Praecis Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4
Founded: West Lebanon NH United States (1993)
Status: Acquired by GlaxoSmithKline (2007)

Organization Overview

First Clinical Trial
2003
NCT00100282
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PRAECIS Pharmaceuticals Inc.

Active Ingredients

Marketed Drugs (1)

abarelix (plenaxis) (NDA)

Drugs in Phase 4 Trials (1)

abarelix (plenaxis) (2 trials)

Drugs in Phase 2 Trials (1)

ppi-1019 (2 trials)

Drugs in Phase 1 Trials (1)

ppi-2458 (1 trial)

Indications

Approved Indications


 

Prostatic Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Prostatic Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 3